



Listing of the Claims:

- 1) (original) A dosage form comprising an alpha-2-adrenergic agonist and a trefoil factor family peptide.
- 2) (original) The dosage form of claim 1 wherein said dosage form is a solid.
- 3) (original) The dosage form of claim 1 wherein said dosage form is a liquid.
- 4) (original) The dosage form of claim 1 wherein said dosage form is a liquid suspension.
- 5) (original) The dosage form of claim 4 wherein the concentration of the alpha-2 adrenergic agonist is from 0.1% to 2%.
- 6) (original) The dosage form of claim 4 wherein the concentration of the alpha-2-adrenergic agonist is about 0.6%.
- 7) (canceled) The method of claim 4 wherein the concentration of the trefoil factor family peptide is from 0.1% to 1%.
- 8) (canceled) The method of claim 4 wherein the concentration of the trefoil factor family peptide is about 0.5%.
- 9) (original) The dosage form of claim 1 wherein said alpha-2-adrenergic agonist is selected from the group consisting of imidazole -2-thiones, quinoxaline derivatives, imino-imidazolines, imidazolines, imidazoles, azepines, thiazines, oxazolines, guanidines, catecholamines, and mixtures thereof, or is a pharmaceutically acceptable salt thereof.
- 10) (original) The dosage form of claim 1 wherein said alpha-2-adrenergic agonist comprises brimonidine or a pharmaceutically acceptable salt thereof.
- 11) (original) The dosage form of claim 1 wherein said alpha-2-adrenergic agonist comprises an imidazole -2-thione or a pharmaceutically acceptable salt thereof.
- 12) (original) The dosage form of claim 1 comprising



or a pharmaceutically acceptable salt thereof.

- 13) (original) The dosage form of claim 1 comprising



or a pharmaceutically acceptable salt thereof.

- 14) (original) The dosage form of claim 1 which further comprises a mucoadhesive agent.
- 15) (original) The dosage form of claim 1 wherein the trefoil factor family peptide is TFF1.
- 16) (original) The dosage form of claim 1 wherein the trefoil factor family peptide is TFF2.
- 17) (original) The dosage form of claim 1 wherein the trefoil factor family peptide is TFF3.
- 18) (canceled) A method of treating glaucoma or reducing intraocular pressure comprising topically administering an alpha-2-adrenergic agonist and a trefoil factor family peptide to an eye of a mammal suffering from glaucoma.
- 19) (canceled) The method of claim 18 wherein said alpha-2-adrenergic agonist and said trefoil factor family peptide are administered in separate compositions.
- 20) (canceled) The method of claim 18 wherein said alpha-2-adrenergic agonist and said trefoil factor family peptide are administered in a single composition.
- 21) (canceled) The method of claim 18 wherein the alpha-2-adrenergic agonist is administered at a concentration of from 0.005% to 0.5%.
- 22) (canceled) The method of claim 18 wherein the alpha-2-adrenergic agonist is administered at a concentration of from 0.02% to 0.2%.
- 23) (canceled) The method of claim 22 wherein the alpha-2-adrenergic agonist is administered at a concentration of about 0.03%.
- 24) (canceled) The method of claim 22 wherein the alpha-2-adrenergic agonist is administered at a concentration of about 0.1%.
- 25) (canceled) The method of claim 18 wherein the trefoil factor family peptide is administered at a concentration from 0.001% to 1%.

- 26) (canceled) The method of claim 22 wherein the trefoil factor family peptide administered at a concentration from 0.01% to 0.5%.
- 27) (canceled) The method of claim 22 wherein the trefoil factor family peptide administered at a concentration from 0.1% to 0.2%.
- 28) (canceled) The method of claim 27 wherein the trefoil factor family peptide is administered at a concentration of about 0.15%.
- 29) (canceled) The method of claim 18 wherein a mucoadhesive agent is also administered to said patient.
- 30) (canceled) The method of claim 18 wherein said trefoil factor family peptide comprises TFF1 or TFF3.
- 31) (canceled) A method of treating a gastrointestinal disorder comprising administering an alpha-2-adrenergic agonist and a trefoil factor family peptide to a mammal suffering from said disorder.
- 32) (canceled) The method of claim 31 wherein the gastrointestinal disorder comprises Crohn's disease, ulcerative colitis, gastritis, irritable bowel disease and chronic visceral pain.
- 33) (canceled) The method of claim 31 wherein the gastrointestinal disorder comprises ulcerative colitis.
- 34) (canceled) The method of claim 31 wherein the gastrointestinal disorder comprises irritable bowel disease.
- 35) (canceled) The method of claim 31 wherein the trefoil factor family peptide is TFF1.
- 36) (canceled) The method of claim 31 wherein the trefoil factor family peptide is TFF3.
- 37) (canceled) The method of claim 31 wherein the alpha-2 adrenergic agonist is administered at a concentration from 0.1% to 2%.
- 38) (canceled) The method of claim 37 wherein the alpha-2-adrenergic agonist is administered at a concentration of about 0.6%.
- 39) (canceled) The method of claim 38 wherein the trefoil factor family peptide is administered at a concentration from 0.1% to 1%

- 40) (canceled) The method of claim 39 wherein the trefoil factor family peptide is administered at a concentration of about 0.5%
- 41) (canceled) The method of claim 18 wherein said alpha-2-adrenergic agonist and said trefoil factor family peptide are administered in separate dosage forms.
- 42) (canceled) The method of claim 18 wherein said alpha-2-adrenergic agonist and said trefoil factor family peptide are administered in a single dosage form.